Bio Stocks™
@BioStocks
Investor/trader focused primarily in the biopharma sector. Tweets are not investment advice and are not recommendations of any kind.
Just realized, I celebrate my 15th Twitterversary this month. Back then, I never imagined this app would become a second home. What started as a place to share ideas has grown into so much more. This platform has allowed me to share biotech insights, bounce ideas, and learn…
$MDGL Secures $500M in Senior Secured Credit from Blue Owl Managed Funds to Further Extend Leadership Position in MASH ir.madrigalpharma.com/news-releases/…
$ATYR Announces Last Patient Visit in Phase 3 EFZO-FIT Study of Efzofitimod in Patients with Pulmonary Sarcoidosis. Topline Data Q3 🔥
$CRDL Announces Database Lock for Phase 2 ARCHER Trial of CardiolRx(TM) in Acute Myocarditis. Topline data expected within the next two weeks.
From the $REPL release: The CRL indicates that the FDA is unable to approve the application in its present form. The FDA has indicated that the IGNYTE trial is not considered to be an adequate and well-controlled clinical investigation that provides substantial evidence of…
$OSCR Announces Preliminary Financial Results for Q2 and Revises FY'25 Guidance. - Raises FY'25 Rev from $11.2B - $11.3B to $12B-$12.2B - Expects Q2 net loss of $228M businesswire.com/news/home/2025…
$SNY to Acquire Vicebio for $1.15 Billion to Bolster Respiratory Vaccine Pipeline
$SRPT "..that Sarepta maintains a productive and positive working relationship with FDA, and it became obvious that maintaining that productive working relationship required this temporary suspension.." - CEO
$SRPT to voluntarily and temporarily pause all shipments of ELEVIDYS for DMD
$SRPT to voluntarily and temporarily pause all shipments of ELEVIDYS for DMD
$AZN plans to invest $50 billion in America for medicines manufacturing and R&D
$SABS ↑ 50% PM $175M Private Placement. RA Capital, Commodore Capital, Vivo Capital, Blackstone Multi-Asset Investing, Spruce Street Capital, Forge Life Science Partners and Woodline Partners LP
$IRON Announces Positive Pre-NDA Meeting and Confirms Plans to Submit NDA for Bitopertin in Erythropoietic Protoporphyria (EPP) in Oct'25
$PMN ProMIS Neurosciences Granted Fast Track Designation by FDA for PMN310 in the Treatment of Alzheimer’s Disease